Advanced glycation end products, oxidant stress and vascular lesions
暂无分享,去创建一个
[1] A. Schmidt,et al. Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes. Modulation by iloprost. , 1996, International angiology : a journal of the International Union of Angiology.
[2] P. Guillausseau,et al. Rapid Publication , 1971, Nature.
[3] J. Chen,et al. The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.
[4] Yong Ming Li,et al. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.
[5] J. Zweier,et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide , 1995, Nature Medicine.
[6] T. Koschinsky,et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[7] G. Otto,et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.
[8] R. Bucala,et al. Identification of N2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. , 1995, Biochemistry.
[9] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[10] R. O’Brien,et al. The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis , 1994, Trends in Endocrinology & Metabolism.
[11] A. Schmidt,et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[12] G. Lutty,et al. Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. , 1994, The Journal of biological chemistry.
[13] G. Striker,et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[14] T. Ikemura,et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. , 1994, Genomics.
[15] H. Vlassara. Recent progress on the biologic and clinical significance of advanced glycosylation end products. , 1994, The Journal of laboratory and clinical medicine.
[16] M. Simionescu,et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. , 1994, The Journal of biological chemistry.
[17] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[18] S. Bursell,et al. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. , 1994, Annual review of medicine.
[19] M. Suthanthiran,et al. Advanced glycosylation endproduct-specific receptors on human and rat T- lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling , 1993, The Journal of experimental medicine.
[20] P. Mcclelland,et al. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus. , 1993, Clinical science.
[21] R. Alexander,et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.
[22] A. Cerami,et al. Mechanism of Inhibition of Advanced Glycosylation by Aminoguanidine in Vitro , 1993 .
[23] M. Huijberts,et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.
[24] B. Ames,et al. Oxidants, antioxidants, and the degenerative diseases of aging. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Bucala,et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[26] N. Morisaki,et al. Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. , 1993, Biochemical and biophysical research communications.
[27] A. Schmidt,et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.
[28] J. V. Hunt,et al. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. , 1993, The Biochemical journal.
[29] A. Gugliucci,et al. Polyclonal immunoglobulin M: location of glycation sites. , 1992, Clinica chimica acta; international journal of clinical chemistry.
[30] S. Krungkrai,et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Brownlee,et al. Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.
[32] L. Mandarino. Current Hypotheses for the Biochemical Basis of Diabetic Retinopathy , 1992, Diabetes Care.
[33] J. Baynes,et al. Role of Oxygen in Cross-Linking and Chemical Modification of Collagen by Glucose , 1992, Diabetes.
[34] Martina,et al. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.
[35] E. Tsilibary,et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. , 1992, The Journal of biological chemistry.
[36] J. Baynes,et al. Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. , 1992, Archives of biochemistry and biophysics.
[37] G. Striker,et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Bucala,et al. Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.
[39] T. E. Whitaker,et al. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. , 1992, The Journal of biological chemistry.
[40] H. Hammes,et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] D. Green,et al. Nonenzymatic glycation of platelet proteins in diabetic patients. , 1991, Seminars in thrombosis and hemostasis.
[42] G. Davı̀,et al. In Vivo Platelet Activation in Diabetes Mellitus , 1991, Seminars in thrombosis and hemostasis.
[43] Z. Makita,et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.
[44] M. Suthanthiran,et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.
[45] Erkki Ruoslahti,et al. Proteoglycans as modulators of growth factor activities , 1991, Cell.
[46] J. Oram,et al. Nonenzymatic Glycosylation of HDL and Impaired HDL-Receptor–Mediated Cholesterol Efflux , 1991, Diabetes.
[47] K. Tracey,et al. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.
[48] E. Cagliero,et al. Characteristics and Mechanisms of High-Glucose–Induced Overexpression of Basement Membrane Components in Cultured Human Endothelial Cells , 1991, Diabetes.
[49] E. Tsilibary,et al. Laminin Alterations After In Vitro Nonenzymatic Glycosylation , 1990, Diabetes.
[50] E. Cagliero,et al. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[51] L. Moldawer,et al. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. , 1989, The Journal of clinical investigation.
[52] H. Gerlach,et al. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.
[53] R. Dean,et al. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.
[54] A. Cerami,et al. Novel Pyrroles from Sulfite-Inhibited Maillard Reactions: Insight into the Mechanism of Inhibition. , 1988 .
[55] E. Cagliero,et al. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. , 1988, The Journal of clinical investigation.
[56] K. Manogue,et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.
[57] A. Cerami,et al. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. , 1988, Archives of biochemistry and biophysics.
[58] A. Cerami,et al. Specific Macrophage Receptor Activity for Advanced Glycosylation End Products Inversely Correlates With Insulin Levels In Vivo , 1988, Diabetes.
[59] M. Bryszewska,et al. Association between the glycation of erythrocyte membrane proteins and membrane fluidity. , 1988, Clinical biochemistry.
[60] F. G. NjorogeS,et al. Mechanism of Formation of the Putative Advanced Glycosylation End , 1988 .
[61] A. Mosca,et al. Glycated proteins in serum: effect of their relative proportions on their alkaline reducing activity in the fructosamine test. , 1987, Clinical chemistry.
[62] C. Kilo,et al. Increased Vascular Permeability in Spontaneously Diabetic BB/W Rats and in Rats With Mild Versus Severe Streptozocin-Induced Diabetes: Prevention by Aldose Reductase Inhibitors and Castration , 1987, Diabetes.
[63] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[64] S. Ranganathan,et al. Metabolism of glycosylated very-low-density lipoproteins in human skin fibroblasts. , 1986, Biochimica et biophysica acta.
[65] A. Cerami,et al. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[66] J. Rosa,et al. Clinical manifestations and erythrocyte adhesion to endothelium in sickle cell syndrome , 1985, American journal of hematology.
[67] R. Nagel,et al. Membrane knobs are required for the microcirculatory obstruction induced by Plasmodium falciparum-infected erythrocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Widness,et al. Nonenzymatic Glycosylation of Erythrocytic Proteins in Normal and Diabetic Subjects: Enzymes of Nucleoside and Nucleotide Metabolism , 1985, Diabetes.
[69] J. Elion,et al. Evidence for nonenzymic glycation of antithrombin III in diabetic patients. , 1985, Clinical chemistry.
[70] M. Bryszewska,et al. Nonenzymatic protein glycosylation. I. Lowered erythrocyte membrane fluidity in juvenile diabetes. , 1985, Annals of clinical research.
[71] S. Pongor,et al. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[72] V. Monnier,et al. Accelerated age-related browning of human collagen in diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[73] J. Witztum,et al. A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. , 1983, The Journal of clinical investigation.
[74] A. Michael,et al. Polyantigenic Expansion of Basement Membrane Constituents in Diabetic Nephropathy , 1983, Diabetes.
[75] M. Sunday. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus. , 1981, The New England journal of medicine.
[76] P. Higgins,et al. Reaction of monosaccharides with proteins: possible evolutionary significance. , 1981, Science.
[77] M. Bitensky,et al. Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[78] J. Miller,et al. Nonenzymatic glycosylation of erythrocyte membrane proteins. Relevance to diabetes. , 1980, The Journal of clinical investigation.
[79] R. Mahley,et al. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. , 1979, The Journal of clinical investigation.
[80] P. Gallop,et al. Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation. , 1979, The Journal of biological chemistry.
[81] H. Bunn,et al. Functional properties of the glycosylated minor components of human adult hemoglobin. , 1979, The Journal of biological chemistry.
[82] D. McMillan,et al. Reduced Erythrocyte Deformability in Diabetes , 1978, Diabetes.
[83] L. Maillard,et al. Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .